Investor Presentation and Investor Meetings
Filed with ASX · · 26 pages · English
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings CallPhiladelphia and Phoenix US, 31 October 2023: Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or “the Company”), is pleased to provide a copy of its updated investor presentation as attached to this release. Senior leadership from the Company will be meeting with investors in Australia this week, to update them on the progress of Sofdra™ towards resubmission of t
Botanix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Botanix Pharmaceuticals
- September 2023 Quarterly Activities Report and Appendix 4C
- Presentation- FDA Letter Requires Patient Instruction Update
- FDA Letter Requires Patient Instruction Update
- Response to ASX Price and Volume Query
- Appendix 4E Preliminary Final Report
Later from Botanix Pharmaceuticals
- Botanix Placement Secures $13.5M to Fund Sofdra Launch Prep
- Successful Completion of $13.5m Institutional Placement
- FDA Confirms Approach to Sofdra NDA Resubmission
- Successful Completion of Human Factors Study
- Botanix Resubmission of NDA for Sofdra Completed
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals